How excluding some benefits from value assessment of new drugs impacts innovation*
Sign Up to like & getrecommendations! Published in 2017 at "Health Economics"
DOI: 10.1002/hec.3507
Abstract: Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently exclude some drugs' option-related benefits, reducing their reimbursement chances, and making them less attractive R&D investments. We develop… read more here.
Keywords: assessment new; excluding benefits; drugs impacts; value assessment ... See more keywords
Antiepileptic drugs: Impacts on human serum paraoxonase‐1
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Biochemical and Molecular Toxicology"
DOI: 10.1002/jbt.21889
Abstract: Serum paraoxonase (PON1) is a key enzyme related to high‐density lipoprotein (HDL)‐cholesterol particle. It can prevent the oxidation of low‐density lipoprotein (LDL) and HDL. The present article focuses on the in vitro inhibition role of… read more here.
Keywords: serum paraoxonase; impacts human; human serum; drugs impacts ... See more keywords